Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2011
vol. 113 abstract:
Review paper
Emerging therapies for the treatment of wet age-related macular degeneration – VEGF Trap-Eye
Robert Rejdak
1, 2, 3
,
Małgorzata Szkaradek
2
,
Paweł Grieb
3
,
Anselm G.M. Jünemann
4
Klinika Oczna 2011, 113 (4): 376-378
Online publish date: 2011/12/04
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialized world. The most severe form of this disease is exudative AMD. It accounts for 10% of cases of AMD and is responsible for approximately 90% cases of severe vision loss due to AMD. Anti-vascular endothelial growth factor (VEGF) therapy changed the standard-of-care for this blinding disease. This article presents one promising new drug for the treatment of exudative AMD – VEGF Trap-Eye.
keywords:
wet age-related macular degeneration, vascular endothelial growth factor, VEGF Trap-Eye, choroidal neovascularization |
|